Upper Versus Lower Gastrointestinal Delivery for Transplantation of Fecal Microbiota in Recurrent or Refractory Clostridium difficile Infection: A Collaborative Analysis of Individual Patient Data From 14 Studies

dc.contributor.authorFuruya-Kanamori, Luis
dc.contributor.authorDoi, Suhail A R
dc.contributor.authorPaterson, David L
dc.contributor.authorHelms, Stefan K
dc.contributor.authorYakob, Laith
dc.contributor.authorMcKenzie, Samantha J
dc.contributor.authorGarborg, Kjetil
dc.contributor.authorEmanuelsson, Frida
dc.contributor.authorStollman, Neil
dc.contributor.authorKronman, Matthew P
dc.contributor.authorClark, Justin
dc.contributor.authorHuber, Charlotte A
dc.contributor.authorRiley, Thomas V
dc.contributor.authorClements, Archie C A
dc.date.accessioned2016-12-13T04:54:27Z
dc.date.available2016-12-13T04:54:27Z
dc.date.issued2016-03-11
dc.description.abstractGOALS The aim of this study was to compare upper gastrointestinal (UGI) versus lower gastrointestinal (LGI) delivery routes of fecal microbiota transplantation (FMT) for refractory or recurrent/relapsing Clostridium difficile infection (CDI). BACKGROUND FMT has been proven to be a safe and highly effective therapeutic option for CDI. Delivery, however, could be via the UGI or LGI routes, and it is unclear as to which route provides better clinical outcome. STUDY A systematic search for studies that reported the use of FMT for CDI treatment was conducted. Individual patient data that included demographic (age and sex) and clinical (route of FMT delivery, CDI outcome after FMT, and follow-up time) information were obtained. Kaplan-Meier cumulative hazard curves and Cox proportional hazard models were used to assess clinical failure after FMT by the route of delivery. RESULTS Data from 305 patients treated with FMT (208 via LGI route and 97 via UGI route) for CDI were analyzed. At 30 and 90 days, the risk of clinical failure was 5.6% and 17.9% in the UGI group compared with 4.9% and 8.5% in the LGI delivery route group, respectively. A time-varying analysis suggested a 3-fold increase in hazard of clinical failure for UGI delivery (hazard ratio, 3.43; 95% confidence interval, 1.32-8.93) in the period after 30 days. CONCLUSIONS FMT delivered via the LGI seems to be the most effective route for the prevention of recurrence/relapse of CDI. A randomized controlled trial is necessary to confirm whether FMT delivered via the LGI is indeed superior to that delivered via the UGI route.en_AU
dc.format.mimetypeapplication/pdfen_AU
dc.identifier.issn0192-0790en_AU
dc.identifier.urihttp://hdl.handle.net/1885/111384
dc.publisherLippincott, Williams & Wilkinsen_AU
dc.rights© 2016 Wolters Kluwer Healthen_AU
dc.sourceJournal of clinical gastroenterologyen_AU
dc.titleUpper Versus Lower Gastrointestinal Delivery for Transplantation of Fecal Microbiota in Recurrent or Refractory Clostridium difficile Infection: A Collaborative Analysis of Individual Patient Data From 14 Studiesen_AU
dc.typeJournal articleen_AU
dcterms.accessRightsOpen Accessen_AU
local.bibliographicCitation.startpage1en_AU
local.contributor.affiliationFuruya-Kanamori, L., Research School of Population Health, The Australian National Universityen_AU
local.contributor.authoremailLuis.Furuya-Kanamori@anu.edu.auen_AU
local.contributor.authoruidu5127170en_AU
local.identifier.doi10.1097/MCG.0000000000000511en_AU
local.identifier.essn1539-2031en_AU
local.identifier.uidSubmittedByu1005913en_AU
local.publisher.urlhttps://www.lww.com/en_AU
local.type.statusPublished Versionen_AU

Downloads

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
884 B
Format:
Item-specific license agreed upon to submission
Description:
Back to topicon-arrow-up-solid
 
APRU
IARU
 
edX
Group of Eight Member

Acknowledgement of Country

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.


Contact ANUCopyrightDisclaimerPrivacyFreedom of Information

+61 2 6125 5111 The Australian National University, Canberra

TEQSA Provider ID: PRV12002 (Australian University) CRICOS Provider Code: 00120C ABN: 52 234 063 906